Axisresearch
- Chemical & Materials
- IMARC GROUP
- 106 pages
- Published: 04-08-2019
The global specialty generics market reached a value of US$ 44.8 Billion in 2018. Specialty generics are generic versions of specialty drugs, once they get off-patent. These drugs are used to treat chronic or complex health conditions including cancer, autoimmune diseases, epilepsy, HIV, Hepatitis, multiple sclerosis, rheumatoid arthritis, etc. Speciality generics are cost-effective as compared to their branded versions as they don’t require costly development and marketing costs.
Compared to traditional generics, the speciality generics market is more concentrated with fewer players due to their complex manufacturing requirements, higher capital costs and relatively lower volumes as a result of smaller patient population. This results in lower price reduction compared to the branded drug and consequently higher margins compared to traditional generics. Speciality generics require special handling, administration, monitoring and generally need prior authorization to order them. The global speciality generics market is currently being driven by several factors such as rising ageing population, patent expiration of a number of branded specialty drugs, increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, HIV, etc., cost containment measures from healthcare providers, growth from emerging markets, etc. Looking forward, the market value is further expected to reach US$ 88.9 Billion by 2024, exhibiting a CAGR of 11.9% during 2019-2024.
IMARC Group’s latest report provides a deep insight into the global specialty generics market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global smart lighting market in any manner.
Report Scope:
Historical, Current and Future Market Trends
Market Breakup by Region:
North America
United States
Canada
Europe
Italy
Germany
Spain
United Kingdom
France
Asia-Pacific
China
India
Japan
South Korea
Latin America
Brazil
Mexico
Middle East Africa
Market Breakup by Route of Administration:
Injectables
Oral
Others
Market Breakup by Indication:
Oncology
Autoimmune Diseases
Infectious Diseases
Others
Market Breakup by Distribution channel:
Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies
Competitive Landscape:
The global specialty generics market consists of numerous manufacturers. Some of the leading players operating in the market are Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc.
Key Questions Answered in This Report:
- How has the global specialty generics market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global specialty generics industry?
- What is the breakup of the global specialty generics market based on the indication?
- What is the breakup of the global specialty generics market based on the route of administration?
- What is the breakup of the global specialty generics market based on the distribution channel?
- \What are the various stages in the value chain of the global specialty generics industry?
- What are the key driving factors and challenges in the global specialty generics market?
- What is the structure of the global specialty generics industry and who are the key players?
- What is the degree of competition in the global specialty generics market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Global Specialty Generics Market: Introduction 5 Why are Specialty Generics So Lucrative? 6 Global Specialty Generics Market 6.1 Market Overview 6.2 Market Performance 6.3 Market Breakup by Route of Administration 6.4 Market Breakup by Indication 6.5 Market Breakup by Distribution Channel 6.6 Market Breakup by Region 6.7 Market Forecast 6.8 SWOT Analysis 6.8.1 Overview 6.8.2 Strengths 6.8.3 Weaknesses 6.8.4 Opportunities 6.8.5 Threats 6.9 Value Chain Analysis 6.10 Porters Five Forces Analysis 6.10.1 Overview 6.10.2 Bargaining Power of Buyers 6.10.3 Bargaining Power of Suppliers 6.10.4 Degree of Competition 6.10.5 Threat of New Entrants 6.10.6 Threat of Substitutes 6.11 Key Market Drivers and Success Factors 7 Market Breakup by Route of Administration 7.1 Injectable 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Oral 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Indication 8.1 Oncology 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Autoimmune Diseases 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Infectious Diseases 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Distribution Channel 9.1 Retail Pharmacies 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Specialty Pharmacies 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Hospital Pharmacies 9.3.1 Market Trends 9.3.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 Market Overview 10.1.2 Market Performance 10.1.3 Market Breakup by Country 10.1.4 United States 10.1.4.1 Market Trends 10.1.4.2 Market Forecast 10.1.5 Canada 10.1.5.1 Market Trends 10.1.5.2 Market Forecast 10.2 Europe 10.2.1 Market Overview 10.2.2 Market Performance 10.2.3 Market Breakup by Country 10.2.4 Italy 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Germany 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 France 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 United Kingdom 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.2.8 Spain 10.2.8.1 Market Trends 10.2.8.2 Market Forecast 10.3 Asia Pacific 10.3.1 Market Overview 10.3.2 Market Performance 10.3.3 Market Breakup by Country 10.3.4 Japan 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 China 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 India 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 South Korea 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Market Overview 10.4.2 Market Performance 10.4.3 Market Breakup by Country 10.4.4 Brazil 10.4.4.1 Market Trends 10.4.4.2 Market Forecast 10.4.5 Mexico 10.4.5.1 Market Trends 10.4.5.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Overview 10.5.2 Market Performance 10.5.3 Market Forecast 11 Competitive Landscape 11.1 Market Structure 11.2 Key Players 11.3 Profiles of Key Players 11.3.1 Teva Pharmaceuticals Industries 11.3.2 Akorn, Inc. 11.3.3 Mylan N.V. 11.3.4 Mallinckrodt 11.3.5 Sandoz International GmbH 11.3.6 Pfizer, Inc. 11.3.7 Sun Pharmaceutical Industries Ltd. 11.3.8 Valeant Pharmaceuticals 11.3.9 Apotex Corp. 11.3.10 Endo International plc. |
Market Breakup by Route of Administration
- Injectable
- Oral
- Others
Market Breakup by Indication
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Others
Market Breakup by Distribution Channel
- Retail Pharmacies
- Specialty Pharmacies
- Hospital Pharmacies
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa